<p>Securian Asset Management Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股减少了 43.7%。该公司在此期间出售了 119,974 股后，持有 154,605 股这家生物制药公司的股票。根据其最近的 SEC 文件，Securian Asset Management Inc. 在辉瑞的持股价值为 3,850,000 美元。</p>
<ul>
<li>5 只高收益股票以保护您的投资组合免受风暴影响</li>
</ul>
<p>其他机构投资者最近也增加或减少了对该公司的持股。Horizon Financial Services LLC 在第四季度将其在辉瑞的持股增加了 174.8%。Horizon Financial Services LLC 目前持有 1,014 股这家生物制药公司的股票，价值 25,000 美元，此前在此期间又购买了 645 股。YANKCOM Partnership 在第四季度购买了辉瑞的新头寸，价值约 28,000 美元。Grey Fox Wealth Advisors LLC 在第三季度购买了辉瑞的新头寸，价值约 29,000 美元。Darwin Wealth Management LLC 在第二季度购买了辉瑞的新头寸，价值约 32,000 美元。最后，Torren Management LLC 在第四季度收购了辉瑞的股份，价值约 34,000 美元。68.36% 的股票由机构投资者持有。</p>
<h2>辉瑞新闻摘要</h2>
<p>以下是本周影响辉瑞的主要新闻：</p>
<ul>
<li>积极情绪：Scotiabank 对辉瑞发起了 <strong>买入</strong> 评级，增强了近期分析师对该股票的信心。辉瑞（PFE）获得了 Scotiabank 的买入评级</li>
<li>积极情绪：Erste Group 略微上调了辉瑞 2026 财年的每股收益预期，强化了盈利保持稳定并符合共识的预期。</li>
<li>积极情绪：最近的报道强调辉瑞第一季度业绩超出预期，销售额好于预期，并且在肿瘤学管线方面取得进展，表明该公司的新药在投资故事中变得越来越重要。辉瑞第一季度业绩超出预期、肿瘤学胜利和专利交易如何改变辉瑞的投资故事</li>
<li>积极情绪：辉瑞的股息仍然是收入投资者的重要吸引力，最近的一篇文章认为高收益仍然得益于管理层的执行和现金流。辉瑞 6.5% 的股息收益率看起来太好而不真实——但管理层刚刚让怀疑者闭嘴</li>
<li>中性情绪：辉瑞正在推进一项新的第一阶段癌症试验，这表明在肿瘤学方面的持续投资，但仍然为时已晚，无法实质性改变近期的财务结果。辉瑞的新第一阶段癌症试验为 PFE 投资者发出新的肿瘤学推动信号</li>
<li>中性情绪：辉瑞还在一项癌症护理行业认可公告中被提及，但该项目主要是声誉性的，单独不会推动股票价格。</li>
<li>消极情绪：辉瑞暂停了一项早期阶段的癌症研究，投资者可能会将终止视为其肿瘤学管线的小挫折，即使财务影响有限。辉瑞终止早期阶段癌症试验：这对 PFE 投资者意味着什么</li>
<li>消极情绪：辉瑞结束了另一项早期阶段的淋巴瘤联合试验，这增加了对某些管线项目可能无法如预期推进的担忧。辉瑞结束早期阶段淋巴瘤联合试验，削减其肿瘤学上行空间的一小部分</li>
</ul>
<h2>辉瑞价格表现</h2>
<ul>
<li>辉瑞在第四季度业绩发布后大幅上涨——但这可能是最重要的催化剂</li>
</ul>
<p>辉瑞股票周一开盘价为 25.65 美元。该股票的 50 天简单移动平均线为 27.14 美元，200 天简单移动平均线为 26.16 美元。该公司的债务与股本比率为 0.67，流动比率为 1.25，速动比率为 0.94。该公司的市值为 1461.7 亿美元，市盈率为 19.58，贝塔值为 0.35。辉瑞公司的 1 年最低价为 21.97 美元，1 年最高价为 28.75 美元。</p>
<p>辉瑞（NYSE:PFE - 获取免费报告）最后一次公布季度财报是在 5 月 5 日，生物制药公司报告该季度每股收益为 0.75 美元，超出市场共识预期的 0.72 美元，超出 0.03 美元。该季度的收入为 144.5 亿美元，而分析师预期为 138.4 亿美元。辉瑞的股本回报率为 19.44%，净利润率为 11.83%。辉瑞的季度收入同比增长 5.4%。在去年同期，该公司每股收益为 0.92 美元。辉瑞已将其 2026 财年的指导目标设定为 2.800-3.000 每股收益。分析师平均预计辉瑞公司在当前财年将发布 2.98 的每股收益。</p>
<h2>辉瑞宣布股息</h2>
<ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？该 ETF 包含它们所有</li>
</ul>
<p>该公司最近还宣布了一项季度股息，将于 6 月 12 日（星期五）支付。5 月 8 日（星期五）的登记投资者将获得 0.43 美元的股息。该股息的除息日为 5 月 8 日（星期五）。这代表着 1.72 美元的年化股息，收益率为 6.7%。辉瑞目前的派息比率为 131.30%。</p>
<h2>分析师设定新目标价</h2>
<p>几位分析师最近对 PFE 股票发表了看法。Cantor Fitzgerald 在 2 月 4 日的报告中重申了对辉瑞的 “中性” 评级，并设定了 27.00 美元的目标价。美国银行在 4 月 9 日的报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并对该股票设定了 “中性” 评级。巴克莱在 2 月 19 日的报告中开始覆盖辉瑞，给予 “减持” 评级，并设定了 25.00 美元的目标价。Wall Street Zen 在周六的报告中将辉瑞的评级从 “持有” 上调至 “买入”。最后，瑞银集团在 4 月 13 日的报告中将辉瑞的目标价从 25.00 美元上调至 27.00 美元，并给予该股票 “中性” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，十二位给予 “持有” 评级，三位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 28.74 美元。</p>
<p><strong>阅读我们关于辉瑞的最新股票报告</strong></p>
<h2>关于辉瑞</h2>
<p>（免费报告）</p>
<p>辉瑞公司（NYSE: PFE）是一家总部位于纽约市的跨国生物制药公司。公司成立于 1849 年，由查尔斯·辉瑞和查尔斯·厄哈特创立，专注于人类健康的广泛药物和疫苗的研究、开发、生产和商业化。其活动涵盖发现研究、临床开发、监管事务、制造和全球商业分销，涉及多个治疗领域。</p>
<p>辉瑞的产品组合和研发管线涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及相当可观的疫苗业务。</p>
<h2>另请参见</h2>
<ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>超越 NVIDIA：强劲势头的 AI 相关股票</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提升，FanDuel 显示复苏迹象</li>
<li>三只医疗股票将从这项重大法案中受益</li>
</ul>
<p><strong>想知道其他对 PFE 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
<p>在考虑辉瑞之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而辉瑞并不在名单上。</p>
<p>虽然辉瑞目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

辉瑞

动态生物技术与基因组 ETF - Invesco

TBXU

<p>Securian Asset Management Inc. 已将其在辉瑞公司的持股减少了 43.7%，在第四季度出售了 119,974 股，剩余 154,605 股，价值 385 万美元。其他机构投资者也调整了在辉瑞的持股。最近的分析师报道持积极态度，斯科舍银行（Scotiabank）首次给予买入评级，Erste Group 则上调了 2026 财年的每股收益预期。然而，辉瑞在早期癌症试验终止方面遭遇挫折，这可能会影响投资者情绪。该股票开盘价为 25.65 美元，市值为 1461.7 亿美元，市盈率为 19.58</p>

<p>Securian Asset Management Inc. reduced its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 43.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The firm owned 154,605 shares of the biopharmaceutical company's stock after selling 119,974 shares during the period. Securian Asset Management Inc.'s holdings in Pfizer were worth $3,850,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Securian Asset Management Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在辉瑞公司（NYSE:PFE - 免费报告）的持股减少了 43.7%。该公司在此期间出售了 119,974 股后，持有 154,605 股这家生物制药公司的股票。根据其最近的 SEC 文件，Securian Asset Management Inc. 在辉瑞的持股价值为 3,850,000 美元。</p>
</div><ul>
<li>5 High-Yield Stocks to Shield Your Portfolio From the Storm</li>
</ul>
<div class="lb-trans"><ul>
<li>5 只高收益股票以保护您的投资组合免受风暴影响</li>
</ul>
</div><p>Other institutional investors also recently added to or reduced their stakes in the company. Horizon Financial Services LLC increased its position in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 645 shares during the period. YANKCOM Partnership bought a new position in Pfizer in the 4th quarter worth approximately $28,000. Grey Fox Wealth Advisors LLC bought a new position in Pfizer in the 3rd quarter worth approximately $29,000. Darwin Wealth Management LLC bought a new position in Pfizer in the 2nd quarter worth approximately $32,000. Finally, Torren Management LLC acquired a new stake in shares of Pfizer during the 4th quarter worth approximately $34,000. 68.36% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>其他机构投资者最近也增加或减少了对该公司的持股。Horizon Financial Services LLC 在第四季度将其在辉瑞的持股增加了 174.8%。Horizon Financial Services LLC 目前持有 1,014 股这家生物制药公司的股票，价值 25,000 美元，此前在此期间又购买了 645 股。YANKCOM Partnership 在第四季度购买了辉瑞的新头寸，价值约 28,000 美元。Grey Fox Wealth Advisors LLC 在第三季度购买了辉瑞的新头寸，价值约 29,000 美元。Darwin Wealth Management LLC 在第二季度购买了辉瑞的新头寸，价值约 32,000 美元。最后，Torren Management LLC 在第四季度收购了辉瑞的股份，价值约 34,000 美元。68.36% 的股票由机构投资者持有。</p>
</div><h2>Pfizer News Summary</h2>
<div class="lb-trans"><h2>辉瑞新闻摘要</h2>
</div><p>Here are the key news stories impacting Pfizer this week:</p>
<div class="lb-trans"><p>以下是本周影响辉瑞的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Scotiabank initiated a <strong>Buy</strong> view on Pfizer, adding to recent analyst confidence in the stock. Pfizer (PFE) Receives a Buy from Scotiabank</li>
<li>Positive Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Pfizer, reinforcing expectations that earnings remain stable and in line with consensus.</li>
<li>Positive Sentiment: Recent coverage highlighted Pfizer’s Q1 beat, better-than-expected sales, and progress in its oncology pipeline, suggesting the company’s newer drugs are becoming more important to the investment story. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story</li>
<li>Positive Sentiment: Pfizer’s dividend remains a major draw for income investors, and a recent article argued that the high yield is still supported by management’s execution and cash flow. Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics</li>
<li>Neutral Sentiment: Pfizer is continuing to advance a new Phase 1 cancer trial, which signals ongoing investment in oncology but is still too early to materially change near-term financial results. Pfizer’s New Phase 1 Cancer Trial Signals Fresh Oncology Push for PFE Investors</li>
<li>Neutral Sentiment: Pfizer was also mentioned in a cancer-care industry recognition announcement, but the item is mostly reputational and unlikely to move the stock on its own.</li>
<li>Negative Sentiment: Pfizer halted an early-stage cancer study, and investors may view the termination as a small setback for its oncology pipeline, even if the financial impact is limited. Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors</li>
<li>Negative Sentiment: Pfizer ended another early-stage lymphoma combination trial, which adds to concerns that some pipeline programs may not advance as hoped. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：Scotiabank 对辉瑞发起了 <strong>买入</strong> 评级，增强了近期分析师对该股票的信心。辉瑞（PFE）获得了 Scotiabank 的买入评级</li>
<li>积极情绪：Erste Group 略微上调了辉瑞 2026 财年的每股收益预期，强化了盈利保持稳定并符合共识的预期。</li>
<li>积极情绪：最近的报道强调辉瑞第一季度业绩超出预期，销售额好于预期，并且在肿瘤学管线方面取得进展，表明该公司的新药在投资故事中变得越来越重要。辉瑞第一季度业绩超出预期、肿瘤学胜利和专利交易如何改变辉瑞的投资故事</li>
<li>积极情绪：辉瑞的股息仍然是收入投资者的重要吸引力，最近的一篇文章认为高收益仍然得益于管理层的执行和现金流。辉瑞 6.5% 的股息收益率看起来太好而不真实——但管理层刚刚让怀疑者闭嘴</li>
<li>中性情绪：辉瑞正在推进一项新的第一阶段癌症试验，这表明在肿瘤学方面的持续投资，但仍然为时已晚，无法实质性改变近期的财务结果。辉瑞的新第一阶段癌症试验为 PFE 投资者发出新的肿瘤学推动信号</li>
<li>中性情绪：辉瑞还在一项癌症护理行业认可公告中被提及，但该项目主要是声誉性的，单独不会推动股票价格。</li>
<li>消极情绪：辉瑞暂停了一项早期阶段的癌症研究，投资者可能会将终止视为其肿瘤学管线的小挫折，即使财务影响有限。辉瑞终止早期阶段癌症试验：这对 PFE 投资者意味着什么</li>
<li>消极情绪：辉瑞结束了另一项早期阶段的淋巴瘤联合试验，这增加了对某些管线项目可能无法如预期推进的担忧。辉瑞结束早期阶段淋巴瘤联合试验，削减其肿瘤学上行空间的一小部分</li>
</ul>
</div><h2>Pfizer Price Performance</h2>
<div class="lb-trans"><h2>辉瑞价格表现</h2>
</div><ul>
<li>Pfizer Pops on Q4 Results—But This May Be the Catalyst That Matters Most</li>
</ul>
<div class="lb-trans"><ul>
<li>辉瑞在第四季度业绩发布后大幅上涨——但这可能是最重要的催化剂</li>
</ul>
</div><p>Shares of PFE stock opened at $25.65 on Monday. The stock's fifty day simple moving average is $27.14 and its 200 day simple moving average is $26.16. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.25 and a quick ratio of 0.94. The firm has a market cap of $146.17 billion, a price-to-earnings ratio of 19.58 and a beta of 0.35. Pfizer Inc. has a one year low of $21.97 and a one year high of $28.75.</p>
<div class="lb-trans"><p>辉瑞股票周一开盘价为 25.65 美元。该股票的 50 天简单移动平均线为 27.14 美元，200 天简单移动平均线为 26.16 美元。该公司的债务与股本比率为 0.67，流动比率为 1.25，速动比率为 0.94。该公司的市值为 1461.7 亿美元，市盈率为 19.58，贝塔值为 0.35。辉瑞公司的 1 年最低价为 21.97 美元，1 年最高价为 28.75 美元。</p>
</div><p>Pfizer (NYSE:PFE - Get Free Report) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.Pfizer's quarterly revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.92 EPS. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>辉瑞（NYSE:PFE - 获取免费报告）最后一次公布季度财报是在 5 月 5 日，生物制药公司报告该季度每股收益为 0.75 美元，超出市场共识预期的 0.72 美元，超出 0.03 美元。该季度的收入为 144.5 亿美元，而分析师预期为 138.4 亿美元。辉瑞的股本回报率为 19.44%，净利润率为 11.83%。辉瑞的季度收入同比增长 5.4%。在去年同期，该公司每股收益为 0.92 美元。辉瑞已将其 2026 财年的指导目标设定为 2.800-3.000 每股收益。分析师平均预计辉瑞公司在当前财年将发布 2.98 的每股收益。</p>
</div><h2>Pfizer Announces Dividend</h2>
<div class="lb-trans"><h2>辉瑞宣布股息</h2>
</div><ul>
<li>Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All</li>
</ul>
<div class="lb-trans"><ul>
<li>Ozempic、Mounjaro、Wegovy 或 Zepbound？该 ETF 包含它们所有</li>
</ul>
</div><p>The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 8th. This represents a $1.72 annualized dividend and a yield of 6.7%. Pfizer's payout ratio is currently 131.30%.</p>
<div class="lb-trans"><p>该公司最近还宣布了一项季度股息，将于 6 月 12 日（星期五）支付。5 月 8 日（星期五）的登记投资者将获得 0.43 美元的股息。该股息的除息日为 5 月 8 日（星期五）。这代表着 1.72 美元的年化股息，收益率为 6.7%。辉瑞目前的派息比率为 131.30%。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><p>Several analysts have recently weighed in on PFE shares. Cantor Fitzgerald reissued a &#34;neutral&#34; rating and set a $27.00 price objective on shares of Pfizer in a report on Wednesday, February 4th. Bank of America decreased their price objective on Pfizer from $27.00 to $26.00 and set a &#34;neutral&#34; rating on the stock in a report on Thursday, April 9th. Barclays started coverage on Pfizer in a report on Thursday, February 19th. They set an &#34;underweight&#34; rating and a $25.00 price objective on the stock. Wall Street Zen raised Pfizer from a &#34;hold&#34; rating to a &#34;buy&#34; rating in a report on Saturday. Finally, UBS Group lifted their price objective on Pfizer from $25.00 to $27.00 and gave the stock a &#34;neutral&#34; rating in a report on Monday, April 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, twelve have given a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of &#34;Hold&#34; and an average price target of $28.74.</p>
<div class="lb-trans"><p>几位分析师最近对 PFE 股票发表了看法。Cantor Fitzgerald 在 2 月 4 日的报告中重申了对辉瑞的 “中性” 评级，并设定了 27.00 美元的目标价。美国银行在 4 月 9 日的报告中将辉瑞的目标价从 27.00 美元下调至 26.00 美元，并对该股票设定了 “中性” 评级。巴克莱在 2 月 19 日的报告中开始覆盖辉瑞，给予 “减持” 评级，并设定了 25.00 美元的目标价。Wall Street Zen 在周六的报告中将辉瑞的评级从 “持有” 上调至 “买入”。最后，瑞银集团在 4 月 13 日的报告中将辉瑞的目标价从 25.00 美元上调至 27.00 美元，并给予该股票 “中性” 评级。一位股票研究分析师给予该股票 “强烈买入” 评级，六位给予 “买入” 评级，十二位给予 “持有” 评级，三位给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的平均评级为 “持有”，平均目标价为 28.74 美元。</p>
</div><p><strong>Read Our Latest Stock Report on Pfizer</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于辉瑞的最新股票报告</strong></p>
</div><h2>About Pfizer</h2>
<div class="lb-trans"><h2>关于辉瑞</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.</p>
<div class="lb-trans"><p>辉瑞公司（NYSE: PFE）是一家总部位于纽约市的跨国生物制药公司。公司成立于 1849 年，由查尔斯·辉瑞和查尔斯·厄哈特创立，专注于人类健康的广泛药物和疫苗的研究、开发、生产和商业化。其活动涵盖发现研究、临床开发、监管事务、制造和全球商业分销，涉及多个治疗领域。</p>
</div><p>Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.</p>
<div class="lb-trans"><p>辉瑞的产品组合和研发管线涵盖肿瘤学、免疫学、心脏病学、内分泌学、罕见疾病、医院急救和抗感染药物，以及相当可观的疫苗业务。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参见</h2>
</div><ul>
<li>Five stocks we like better than Pfizer</li>
<li>Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum</li>
<li>Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players</li>
<li>Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery</li>
<li>3 Healthcare Stocks Set to Benefit From the One Big Beautiful Bill</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过辉瑞</li>
<li>超越 NVIDIA：强劲势头的 AI 相关股票</li>
<li>量子财报季正在升温——关注两大主要参与者</li>
<li>Flutter 在财报后看到提升，FanDuel 显示复苏迹象</li>
<li>三只医疗股票将从这项重大法案中受益</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding PFE?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).</p>
<div class="lb-trans"><p><strong>想知道其他对 PFE 持有的对冲基金吗？</strong> 访问 HoldingsChannel.com，获取辉瑞公司（NYSE:PFE - 免费报告）的最新 13F 文件和内部交易信息。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPVBGRQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=PFE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Pfizer Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在辉瑞吗？</h2>
</div><p>Before you consider Pfizer, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑辉瑞之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户在更广泛的市场注意到之前立即购买的股票……而辉瑞并不在名单上。</p>
</div><p>While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然辉瑞目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Securian Asset Management Inc. Sells 119,974 Shares of Pfizer Inc. $PFE

- Securian Asset Management Inc. 在第四季度将对 Pfizer 的持股减少 43.7%。  
- Horizon Financial Services LLC 的持股增加 174.8%，另有多家机构新增投资。  
- Pfizer 最近宣布季度分红 0.43 美元，年化收益率为 6.7%。

Securian 资产管理公司出售了辉瑞公司 119,974 股股票